狗带

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

A | (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 。

B | 8月26日讯在新赛季的首轮意甲联赛，罗马主场4-0大胜佛罗伦萨。波兰名宿博涅克过去曾在罗马效力过，目前担任欧足联副主席的他在接受采访时进行了点评。罗马在本赛季能争夺意甲冠军吗？我建议大家冷静一些。罗马的开局很好，但我不会现在就得出结论。

C | 赛季很漫长，罗马还需要参加至少8场欧冠比赛以及意大利杯比赛。罗马开局不错，但我们面对的对手是一支刚组建不久还在各自为战的新球队。佛罗伦萨在比赛中没有制造任何困难，而罗马顺利把握了机会。你认为谁是意甲夺冠热门？我认为，目前国米依然是意甲最强球队，罗马和其他球队排在第二梯队。但是，我认为加斯佩里尼的这支罗马真的是一个大家庭，每个人都非常清楚自己的位置。在首轮意甲联赛中，马伦上演帽子戏法，而迪巴拉助攻3次，你对这对罗马锋线搭档有何评价？我不知道当初是谁在罗马提出引进马伦的，但别忘了当时他在维拉还只是替补。罗马签下马伦只花了2500万欧元，如今他至少值7000万至8000万欧元。至于迪巴拉，如果他能一直保持健康，现在可能会在皇马或巴萨效力。迪巴拉每次触球都可能创造出机会，昨天我看到他的状态很好。不过目前我暂且保留对他的过高期望，因为之前他曾在罚一个点球时受伤。